Ryan Scott

Articles

Onvansertib Induces Preclinical Anti-Tumorigenic Effects in Endometrioid Endometrial Cancer

January 27th 2024

Nikita Sinha, MD, discusses the effects of onvansertib on cellular proliferation, adhesion, apoptosis, and stress in endometrial cancer cells.

Toxicities From Lenvatinib/Pembrolizumab Associated With Treatment Response in Gynecologic Malignancies

January 26th 2024

Paulina J. Haight, MD, discusses the association between the occurrence of toxicities with response to treatment with lenvatinib and pembrolizumab.

Real-World Findings Emphasize the Need for Early Genetic Testing in HRR-Mutated mCRPC

January 25th 2024

Patients with HRR gene–mutated mCRPC treated with olaparib have an unmet need for early and consistent genetic testing to optimize treatment outcomes.

Porter Details Future Directions For Treating Patients With KRAS G12C-Mutated NSCLC

January 22nd 2024

Jason Porter, MD, discusses the progress in the development of treatment options for patients with KRAS G12C-mutated non–small cell lung cancer.

Continued Investigations are Pertinent for FDA Approvals in the Treatment of Patients With EGFR-mutated NSCLC

January 18th 2024

Jason Porter, MD, discusses the implications of adjuvant EGFR TKI use, the importance of the potential FDA approval of osimertinib in EGFR+ NSCLC, & more.

Disitamab Vedotin Combos Show Efficacy in HER2+ and HER2-Low Breast Cancers

January 17th 2024

Disitamab vedotin alone and with ICIs, TKIs, or other antiangiogenic agents had consistent efficacy in patients with HER2-positive or -low breast cancers.

Sacibertinib Plus Endocrine Therapy Shows Early Safety, Activity in ER+/HER2+ Breast Cancer

January 16th 2024

Sacibertinib plus endocrine therapy had acceptable safety with early clinical activity in patients with ER+/HER2+ metastatic breast cancer.

Sequential Neoadjuvant HER2 Blockade Plus Polychemotherapy Elicits Antitumor Activity in HER2+ Breast Cancer

January 13th 2024

Neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide, followed by a taxane, concomitant with trastuzumab/pertuzumab elicited responses in patients with HER2+ breast cancer.

Camrelizumab With Rivoceranib Elicits PFS and OS Benefit Over Sorafenib in Unresectable HCC

January 12th 2024

Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib in unresectable HCC, based on data from the phase 3 CARES-310 trial.

Neoadjuvant Cemiplimab Prolongs Survival in Stage II to IV CSCC

January 12th 2024

Neil D. Gross, MD, FACS, shares how neoadjuvant cemiplimab followed by surgery improved EFS in patients with stage II-IV cutaneous squamous cell carcinoma.

Engineered Bone Marrow Shows Preclinical Potential in Osteosarcoma

January 10th 2024

R. Lor Randall, MD, FACS, emphasizes the overall potential for investigating the utility of engineered bone marrow in patients with osteosarcoma.

Cobolimab/Dostarlimab Combination Shows Initial Efficacy and Safety Signals in Advanced NSCLC

January 10th 2024

Cobolimab plus dostarlimab-gxly showed activity and acceptable safety across all dose levels assessed in patients with non–small cell lung cancer.

Allegheny Health Network Oncology Experts Dive Into Updates Within the Gynecologic Oncology Space

January 10th 2024

Eirwen M. Miller, MD, spotlights updated data within the endometrial, cervical, and ovarian cancer spaces following the 2023 ESMO Congress.

2023 Yields Several Promising Trial Updates in dMMR/pMMR Endometrial Cancer

January 9th 2024

Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.

A Journey Across the Atlantic Leads to a Path in Surgical Oncology

January 6th 2024

A planned 5-year trip in the United States coupled with a thirst for knowledge turned into a lifetime of surgical oncology accomplishments for Eleftherios “Terry” Mamounas, MD, MPH.

Lenvatinib/Pembrolizumab/Chemo Induces Inferior OS vs Pembrolizumab/Chemo in Previously Untreated NSCLC

January 5th 2024

Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.

Oncolytic Adenovirus TILT-123 Combined With TIL Therapy Is Safe in Metastatic Melanoma

January 5th 2024

Intravenous and intratumoral treatment with TILT-123 was found to be safe and feasible, with no dose-limiting toxicities when given alone or in combination with tumor infiltrating lymphocyte therapy in patients with advanced, metastatic melanoma.

Selinexor/Ruxolitinib Combo Is Tolerable, Shows Durable Spleen, Symptom Responses in JAK Inhibitor–Naive Myelofibrosis

January 4th 2024

The oral XPO1 inhibitor selinexor in combination with ruxolitinib was associated with a tolerable and manageable adverse effect profile and elicited signals of clinical efficacy in patients with JAK inhibitor–naive myelofibrosis.

Gynecologic Oncologists Highlight Ongoing Areas of Exploration Throughout the Treatment Armamentarium

December 22nd 2023

Michael P. Stany, MD, discusses the optimization of PARP inhibitors in the upfront maintenance setting of ovarian cancer, the benefit of novel targets and immunotherapy combinations, and the role of immunotherapy in the treatment of advanced endometrial cancer.

Sacituzumab Govitecan Plus Pembrolizumab Elicits Antitumor Activity in NSCLC

December 22nd 2023

Sandip P. Patel, MD, discusses the exploration of sacituzumab govitecan in the EVOKE-01 and EVOKE-02 trials in NSCLC and expands on future treatment directions with the agent in this patient population.